Understanding Factor V Leiden Thrombophilia (FVL), also known as Factor V Leiden Mutation, requires accurate clinical documentation and medical coding. This resource provides information on FVL diagnosis, Activated Protein C Resistance, and associated healthcare implications. Learn about genetic testing, treatment options, and risk factors for this inherited thrombophilia.
Also known as
Factor V Leiden thrombophilia
Inherited disorder increasing blood clot risk.
Personal history of other coagulation defects
Past diagnosis of a blood clotting disorder, including Factor V Leiden.
Other specified venous embolism and thrombosis
Venous blood clots not categorized elsewhere, potentially linked to Factor V Leiden.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Factor V Leiden confirmed by molecular testing?
When to use each related code
| Description |
|---|
| Inherited blood clotting disorder |
| Prothrombin G20210A mutation |
| Antithrombin deficiency |
Coding F5 mutation without specifying heterozygous/homozygous type can lead to inaccurate risk assessment and claims.
Documenting APC resistance without confirming FVL mutation may cause incorrect coding and affect quality reporting.
Incomplete history of FVL (e.g., active vs. history of) can lead to coding errors impacting patient safety and reimbursement.
Q: What are the most effective diagnostic strategies for confirming Factor V Leiden Thrombophilia in patients with suspected thrombophilia or recurrent venous thromboembolism?
A: Diagnosing Factor V Leiden Thrombophilia (FVL or Factor V Leiden Mutation) relies primarily on genetic testing, specifically PCR-based assays, to detect the specific mutation (G1691A) responsible for Activated Protein C Resistance. These tests are highly sensitive and specific. While functional assays for Activated Protein C Resistance (APC resistance) can be used, they are less specific than genetic testing as other factors can influence APC resistance. For patients presenting with recurrent venous thromboembolism or a strong family history of thrombophilia, genetic testing for FVL should be considered a first-line diagnostic approach. Consider implementing genetic testing algorithms that also screen for other inherited thrombophilias like Prothrombin G20210A mutation, especially in cases with a strong family history. Explore how pre-test probability assessments, based on clinical factors and family history, can further optimize diagnostic accuracy. Learn more about interpreting genetic test results for FVL in various clinical scenarios.
Q: How should I manage anticoagulation therapy in a pregnant patient with Factor V Leiden Thrombophilia and a history of deep vein thrombosis?
A: Managing anticoagulation in pregnant patients diagnosed with Factor V Leiden Thrombophilia and prior Deep Vein Thrombosis (DVT) requires careful consideration of both maternal and fetal risks. Low-molecular-weight heparin (LMWH), such as enoxaparin or dalteparin, is generally the preferred anticoagulant throughout pregnancy and for 6-12 weeks postpartum due to its safety profile and lack of placental transfer. The dosage should be adjusted according to body weight and anti-Xa levels. Unfractionated heparin can be used near the time of delivery due to its short half-life. Warfarin is contraindicated during the first trimester and near term due to teratogenic and bleeding risks, respectively. Explore the latest guidelines on risk stratification for pregnant women with FVL to tailor anticoagulation strategies based on individual risk factors. Consider implementing a postpartum thromboprophylaxis plan based on individual risk assessment. Learn more about the role of thrombophilia clinics in managing complex cases of pregnancy and thrombophilia.
Patient presents with concerns regarding Factor V Leiden Thrombophilia, also known as Factor V Leiden Mutation or FVL, and Activated Protein C Resistance. Assessment includes detailed history focusing on personal and family history of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as arterial thrombosis, pregnancy complications such as recurrent miscarriage or preeclampsia, and any history of unusual or recurrent clotting events. Diagnostic testing for Factor V Leiden mutation was ordered to evaluate for inherited thrombophilia. Genetic testing, specifically for the G1691A mutation in the Factor V gene, is the gold standard for diagnosis. This patient's presentation and positive test results confirm the diagnosis of Factor V Leiden Thrombophilia. Differential diagnoses considered included other inherited thrombophilias such as Prothrombin G20210A mutation, Protein C and Protein S deficiency, and antithrombin deficiency. Patient education was provided regarding the increased risk of thromboembolic events and potential complications. Management will be tailored to the patient's individual risk factors and may include prophylactic anticoagulation with agents such as low molecular weight heparin (LMWH) or warfarin, particularly in high-risk situations such as surgery, prolonged immobilization, or pregnancy. The patient was counseled on lifestyle modifications including maintaining a healthy weight, regular exercise, and smoking cessation to minimize modifiable risk factors for thrombosis. Follow-up appointments will be scheduled for ongoing monitoring and management as needed. ICD-10 code I82.2 (Factor V Leiden mutation) is applicable for billing and coding purposes. This documentation supports the medical necessity for testing and treatment related to Factor V Leiden Thrombophilia.